Q2 2025 Ultragenyx Pharmaceutical Inc Earnings Call Transcript
Key Points
- Ultragenyx Pharmaceutical Inc (RARE) reported a 20% revenue growth in the first half of 2025, reaching $306 million.
- The company has five Phase 3 clinical programs fully enrolled or at the BLA submission stage, showcasing a robust pipeline.
- GTX-102 received breakthrough therapy designation from the FDA, indicating its potential as a significant treatment for Angelman syndrome.
- The commercial team successfully generated double-digit revenue growth, with Crysvita, Dojolvi, Evkeeza, and Mepsevii contributing to the top line.
- Ultragenyx remains on track to achieve GAAP profitability by 2027, focusing on revenue growth and cost management.
- The company reported a net loss of $115 million for the quarter, highlighting ongoing financial challenges.
- Operating expenses were high at $274 million, including significant R&D and SG&A costs.
- Ultragenyx received a complete response letter for UX111, delaying its approval and requiring further FDA interactions.
- There is potential quarter-to-quarter revenue variability due to uneven ordering patterns for Crysvita in Latin America.
- The company anticipates a modest increase in net cash used in operations for 2025 compared to 2024, driven by timing delays in certain programs.
Good afternoon, and welcome to the Ultragenyx second-quarter 2025 financial results conference call. (Operator Instructions) At the end of the prepared remarks, you will have an opportunity to ask questions during the Q&A portion of the call.
It is now my pleasure to turn the call to Josh Higa, Vice President of Investor Relations.
Thank you. We have issued a press release detailing our financial results, which you can find on our website at ultragenyx.com. Joining me on this call are Emil Kakkis, Chief Executive Officer and President; Erik Harris, Chief Commercial Officer; Howard Horn, Chief Financial Officer; and Eric Crombez, Chief Medical Officer.
I'd like to remind everyone that during today's call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. Please refer to the risk factors discussed in our latest SEC filings.
I'll now turn the call
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
